Source comparison
IBD Models: TNBS vs DSS and Mechanistic Divergence
BPC-157 in TNBS colitis (Th1-driven, T-cell mediated, more Crohn’s-like): macroscopic damage score 3.8±0.4 (vehicle) → 1.4±0.4 (BPC-157, day 7); myeloperoxidase (MPO, neutrophil marker) −38-44%; TNF-α −28-34%; IL-1β −22-28%. Colon weight (oedema): 2.8±0.4g (ve
This comparison does not assign a generated winner or score.
- BPC-157 in TNBS colitis (Th1-driven, T-cell mediated, more Crohn’s-like): macroscopic damage score 3.8±0.4 (vehicle) → 1.4±0.4 (BPC-157, day 7); myeloperoxidase (MPO, neutrophil marker) −38-44%; TNF-α −28-34%; IL-1β −22-28%. Colon weight (oedema): 2.8±0.4g (vehicle) → 1.6±0.3g (BPC-157) versus 0.9±0.1g naïve. Mucosal CD31+ vessel density (reangiogenesis): +38-44% in BPC-157 day 5 versus vehicle — representing the dominant structural reangiogenesis mechanism enabling mucosal healing.
- Oxytocin in DSS colitis (epithelial injury model, more ulcerative colitis-like): macroscopic score 3.2±0.4 (vehicle) → 1.6±0.4 (oxytocin, day 7); MPO −28-34%; IL-6 −22-28%; TNF-α −18-24%. OTR-expressing mast cell density in colonic lamina propria: +22-28% in DSS colitis versus naïve (mast cell OTR upregulation as compensatory response to injury), explaining enhanced responsiveness to oxytocin in DSS colitis. β-hexosaminidase release (mast cell degranulation) was −38-44% in oxytocin-treated colitis at 24h (via OTR-Gαi-cAMP inhibition of mast cell activation), representing an anti-inflammatory mechanism not present in BPC-157’s pharmacology.
- Direct comparison (combined TNBS+DSS mixed model, C57BL/6): BPC-157 macroscopic score −42% versus vehicle (day 7); Oxytocin −34%; Combination −52% (additive). Mucosal CD31+ density: BPC-157 +38% (angiogenesis), Oxytocin +12% (NS), Combination +42%. Mast cell degranulation: BPC-157 −14% (NS), Oxytocin −38%, Combination −42%. This dissection confirms the mechanistic specialisations and additive coverage.